Exagen Inc (NASDAQ: XGN) kicked off on Friday, down -7.90% from the previous trading day, before settling in for the closing price of $10.38. Over the past 52 weeks, XGN has traded in a range of $2.43-$12.23.
A company in the Healthcare sector has jumped its sales by 19.20% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -4.07%. With a float of $15.10 million, this company’s outstanding shares have now reached $22.51 million.
Exagen Inc (XGN) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Diagnostics & Research Industry. The insider ownership of Exagen Inc is 33.35%, while institutional ownership is 43.57%. The most recent insider transaction that took place on Oct 16 ’25, was worth 375,598. In this transaction President and CEO of this company sold 31,787 shares at a rate of $11.82, taking the stock ownership to the 714,427 shares. Before that another transaction happened on Sep 02 ’25, when Company’s Chief Financial Officer sold 20,466 for $9.79, making the entire transaction worth $200,362. This insider now owns 269,026 shares in total.
Exagen Inc (XGN) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.2 earnings per share (EPS), higher than consensus estimate (set at -0.24) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.79% during the next five years compared to 19.20% growth over the previous five years of trading.
Exagen Inc (NASDAQ: XGN) Trading Performance Indicators
Take a look at Exagen Inc’s (XGN) current performance indicators. Last quarter, stock had a quick ratio of 3.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.93, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.47 in one year’s time.
Technical Analysis of Exagen Inc (XGN)
Let’s dig in a bit further. During the last 5-days, its volume was 0.78 million. That was better than the volume of 0.24 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 23.39%.
During the past 100 days, Exagen Inc’s (XGN) raw stochastic average was set at 52.83%, which indicates a significant increase from 10.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.48 in the past 14 days, which was higher than the 0.42 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.69, while its 200-day Moving Average is $7.19. However, in the short run, Exagen Inc’s stock first resistance to watch stands at $10.23. Second resistance stands at $10.90. The third major resistance level sits at $11.40. If the price goes on to break the first support level at $9.07, it is likely to go to the next support level at $8.57. Assuming the price breaks the second support level, the third support level stands at $7.90.
Exagen Inc (NASDAQ: XGN) Key Stats
The company with the Market Capitalisation of 216.66 million has total of 22,663K Shares Outstanding. Its annual sales at the moment are 55,640 K in contrast with the sum of -15,120 K annual income. Company’s last quarter sales were recorded 17,200 K and last quarter income was -4,440 K.
